News

Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...
Eli Lilly stock sell-off was 'overreaction': Analysts
Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...
Eli Lilly sues telehealth companies for selling Mounjaro, Zepbound compounds
Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...
Why Eli Lilly Stock Is Sinking Today
Shares of Eli Lilly ( LLY -10.79%) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m. ET. The leg down comes as ...
Eli Lilly stock slips despite earnings beat, reaffirmed 2025 guidance
Eli Lilly's weekly prescription data for Zepbound is up 354% year over year while Novo Nordisk's Wegovy is up just 61%.
Eli Lilly CEO Urges Trump to Ease Up on Tariffs, Extend 2017 Tax Cuts
The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its [tariff rollout]( ...
BioSpace3d
Lilly’s Revenue Leaps 45% Thanks to Zepbound, Mounjaro, Of Course
To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...
Eli Lilly beats Q1 profit estimates on strength of diabetes drug
Eli Lilly on Thursday reported first-quarter profit above Wall Street estimates, helped by strong sales of its widely popular weight-loss and diabetes drugs Zepbound and Mounjaro. On an adjusted basis ...